Zug, Zug, Switzerland The main office of represented VC is situated in the Zug. The company was established in Europe in Switzerland.
Among the most popular portfolio startups of the fund, we may highlight ARMO BioSciences, Harmony Biosciences, Vivoryon Therapeutics. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Medical, Medical Device. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. The fund has exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager.
Besides them, we counted 4 critical employees of this fund in our database.
The top activity for fund was in 2007. Despite it in 2019 the fund had an activity. The typical startup value when the investment from HBM Healthcare Investments AG is 100-500 millions dollars. Speaking about the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this HBM Healthcare Investments AG performs on 3 percentage points less the average number of lead investments. The fund is generally included in 2-6 deals every year. The increased amount of exits for fund were in 2018. Deals in the range of 10 - 50 millions dollars are the general things for fund.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the HBM Healthcare Investments AG, startups are often financed by OrbiMed, Kleiner Perkins, Novo Holdings. The meaningful sponsors for the fund in investment in the same round are OUP (Osage University Partners), Novartis Venture Fund, Venrock. In the next rounds fund is usually obtained by SV Health Investors, Alta Partners, Maverick Ventures.
Related Funds
Funds with similar focus
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Sphingotec GmbH | $5M | 08 Aug 2024 | Hohen Neuendorf, Brandenburg, Germany | ||
Bluejay Therapeutics | $182M | 09 May 2024 | - | ||
Karius | $100M | 02 May 2024 | Redwood City, California, United States | ||
Esker Therapeutics | $259M | 06 Mar 2024 | - | ||
Shape Memory Medical | $38M | 04 Mar 2024 | San Jose, California, United States | ||
Odyssey Therapeutics | $101M | 05 Dec 2023 | Cambridge, Massachusetts, United States | ||
Upstream Bio | $200M | 08 Jun 2023 | Waltham, Massachusetts, United States | ||
Numab | 05 Dec 2022 | Zurich, Switzerland | |||
Farmalisto | 28 Nov 2022 | Buenaventura, Valle del Cauca, Colombia |
– NiKang Therapeutics Inc. announced the completion of an oversubscribed $200m series C financing led by Cormorant Asset Management, HBM Healthcare Investments and Octagon Capital Advisors with participations from a premier syndicate of funds including new investors EcoR1 Capital, Perceptive Advisors, Wellington Management, Ally Bridge Group, Pavilion Capital, funds and accounts managed by BlackRock, RA Capital Management, Surveyor Capital (a Citadel company), Samsara BioCapital, PFM Health Sciences, Invus, Janus Henderson Investors and Logos Capital.
– All existing investors including CBC Group, RTW Investments, LP, Lilly Asia Ventures, Matrix Partners China, and Casdin Capital participated in the financing.
– Pyxis Oncology from Longwood Fund has closed a $152m Series B financing.
– The round was led by Arix Bioscience and co-led by RTW Investments, LP.
– New investors included Perceptive Advisors, RA Capital Management, Pfizer Ventures, BVF Partners, L.P., Janus Henderson Investors, Cormorant Asset Management, HBM Healthcare Investments, funds managed by Tekla Capital Management LLC, Acuta Capital Partners, Ridgeback Capital Investments, Surveyor Capital (a Citadel company), Laurion Capital Management, Logos Capital and LifeSci Venture Partners.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Sphingotec GmbH | $5M | 08 Aug 2024 | Hohen Neuendorf, Brandenburg, Germany | ||
Bluejay Therapeutics | $182M | 09 May 2024 | - | ||
Karius | $100M | 02 May 2024 | Redwood City, California, United States | ||
Esker Therapeutics | $259M | 06 Mar 2024 | - | ||
Shape Memory Medical | $38M | 04 Mar 2024 | San Jose, California, United States | ||
Odyssey Therapeutics | $101M | 05 Dec 2023 | Cambridge, Massachusetts, United States | ||
Upstream Bio | $200M | 08 Jun 2023 | Waltham, Massachusetts, United States | ||
Numab | 05 Dec 2022 | Zurich, Switzerland | |||
Farmalisto | 28 Nov 2022 | Buenaventura, Valle del Cauca, Colombia |
